OnePin Peptide Library · Metabolic
Exenatide
Byetta · Bydureon
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA (2005) for the treatment of type 2 diabetes mellitus. Exenatide shares approximately 53% sequence homology with human GLP-1 but is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), giving it a clinically useful duration of action.,Exenatide is marketed in two formulations: Byetta (immediate-release, twice daily) approved in 2005, and Bydureon/Bydureon BCise (extended-release microsphere formulation, once weekly) approved in 2012. Both are subcutaneous injections. The extended-release formulation uses biodegradable poly(D,L-lactide-co-glycolide) microspheres to achieve sustained drug release over 7 days from a single injection.,As one of the earliest GLP-1 RAs, exenatide has an extensive clinical database including the EXSCEL cardiovascular outcomes trial. While it demonstrated cardiovascular safety (non-inferiority to placebo), it did not achieve statistical significance for cardiovascular superiority, unlike some later GLP-1 RAs such as liraglutide and semaglutide. Exenatide remains a viable treatment option, though newer agents in the class have generally shown greater efficacy for both glycemic control and weight loss.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Potently activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells and suppressing inappropriate postprandial glucagon secretion from alpha cells. The glucose-dependent mechanism reduces hypoglycemia risk.,Significantly slows gastric emptying (especially the immediate-release formulation), reducing the rate of glucose appearance in the bloodstream after meals and contributing to satiety and reduced food intake.,Acts on hypothalamic appetite-regulating centers to promote satiety and reduce caloric intake, contributing to the modest weight loss observed with treatment.
Potently activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells and suppressing inappropriate postprandial glucagon secretion from alpha cells. The glucose-dependent mechanism reduces hypoglycemia risk.,Significantly slows gastric emptying (especially the immediate-release formulation), reducing the rate of glucose appearance in the bloodstream after meals and contributing to satiety and reduced food intake.,Acts on hypothalamic appetite-regulating centers to promote satiety and reduce caloric intake, contributing to the modest weight loss observed with treatment.
What to expect
Days 1-14: Immediate postprandial glucose improvement (Byetta). GI side effects peak and begin to subside. Appetite reduction noticeable.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Pharmacokinetics
Storage. Byetta: Store refrigerated at 2-8C. After first use, may be kept at room temperature (up to 25C) for up to 30 days. Bydureon: Store refrigerated. Protect from light.
Regulatory status
FDA-approved. Byetta (exenatide immediate-release) approved 2005 for type 2 diabetes. Bydureon (exenatide extended-release) approved 2012. Also EMA-approved. Marketed by AstraZeneca. Prescription drug in all markets.
Put it to work
Calculate, log & track
Open Exenatide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Exenatide in the app →Go deeper
The guide & community
The complete Exenatide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗